| Literature DB >> 26569304 |
Andrea Didier1, Nadja Jeßberger2, Victoria Krey3, Richard Dietrich4, Siegfried Scherer5, Erwin Märtlbauer6.
Abstract
The ability of Bacillus cereus to cause foodborne toxicoinfections leads to increasing concerns regarding consumer protection. For the diarrhea-associated enterotoxins, the assessment of the non-hemolytic enterotoxin B (NheB) titer determined by a sandwich enzyme immunoassay (EIA) correlates best with in vitro cytotoxicity. In general, the regulation of enterotoxin expression of B. cereus is a coordinately-regulated process influenced by environmental, and probably also by host factors. As long as these factors are not completely understood, the currently-applied diagnostic procedures are based on indirect approaches to assess the potential virulence of an isolate. To date, sandwich EIA results serve as a surrogate marker to categorize isolates as either potentially low or highly toxic. Here, we report on a single amino acid exchange in the NheB sequence leading to an underestimation of the cytotoxic potential in a limited number of strains. During the screening of a large panel of B. cereus isolates, six showed uncommon features with low sandwich EIA titers despite high cytotoxicity. Sequence analysis revealed the point-mutation (Glu)151(Asp) in the potential binding region of the capture antibody. Application of this antibody also results in low titers in an indirect EIA format and shows variable detection intensities in Western-immunoblots. A commercially-available assay based on a lateral flow device detects all strains correctly as NheB producers in a qualitative manner. In conclusion, isolates showing low NheB titers should additionally be assayed in an indirect EIA or for their in vitro cytotoxicity to ensure a correct classification as either low or highly toxic.Entities:
Keywords: Bacillus cereus; Duopath®; non-hemolytic enterotoxin B; point mutation
Mesh:
Substances:
Year: 2015 PMID: 26569304 PMCID: PMC4663526 DOI: 10.3390/toxins7114655
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Strains investigated in this study. The last column shows the results of sequencing. WB: Western blot.
| Strain Number | Origin | Type | AA or Mutation at Position 151 |
|---|---|---|---|
| MHI 241 | stew with vegetables | high toxicity | Glu |
| MHI 3178 | infant food | low toxicity | Glu |
| MHI 1440 | unknown | 151mutant | Glu › Asp |
| MHI 1541 | unknown | 151mutant | Glu › Asp |
| MHI 1668 | infant food | 151mutant | Glu › Asp |
| MHI 2970 | milk powder | 151mutant | Glu › Asp |
| MHI 3173 | human faeces | 151mutant | Glu › Asp |
| MHI 3225 | coffee cream | 151mutant | Glu › Asp |
| MHI 1430 | unknown | intermediate performance in EIA and WB | Glu |
| MHI 1444 | unknown | intermediate performance in EIA and WB | Glu |
| MMI 1758 | unknown | intermediate performance in EIA and WB | Glu |
Cytotoxicity and toxin titers. All strains have been tested by the Vero, as well as CaCo-2 cytotoxicity assay, an in-house sandwich EIA, and two in-house indirect EIAs. Titers indicated are means and SD of triplicates. The strains reacted positively in the Duopath® test; Duopath® tests were performed twice.
| Strain | Cytotoxicity titer (Vero cells) | Cytotoxicity titer (CaCo-2 cells) | Sandwich EIA titer | Indirect EIA 1E11 titer | Indirect EIA 2B11 titer | Duopath® |
|---|---|---|---|---|---|---|
| MHI 241 | 1381 (±8.0) | 358 (±46.2) | 27072 (±2841.9) | 2669 (±128.7) | 118 (±0.7) | + |
| MHI 3178 | 16 (±4.2) | 4 (±0.3) | 192 (±7.8) | 113 (±9.2) | 27 (±2.8) | + |
| MHI 1440 | 218 (±20.5) | 202 (±39.2) | 5.4 (±0.2) | 583 (±33.9) | 2.6 (±1.3) | + |
| MHI 1541 | 533 (±46.0) | 198 (±22.4) | 19 (±1.4) | 775 (±76.4) | 6.7 (±1.1) | + |
| MHI 1668 | 628 (±36.8) | 157 (±26.6) | 47.5 (±0.7) | 2330 (±753.1) | 47.5 (±0.7) | + |
| MHI 2970 | 755 (±4.2) | 345 (±80.2) | 41.5 (±2.1) | 1204 (±125.2) | 11 (±1.3) | + |
| MHI 3173 | 1210 (±253.1) | 271 (±46.3) | 38.5 (±2.7) | 1682 (±14.1) | 5.7 (±2.0) | + |
| MHI 3225 | 1274 (±247.5) | 200 (±10.2) | 36.5 (±0.7) | 1692 (±14.1) | 6.9 (±1.3) | + |
| MHI 1430 | 679 (±89.0) | 280 (±15.4) | 467 (±26.9) | 2383 (±501.3) | 51 (±9.9) | + |
| MHI 1444 | 740 (±162.3) | 508 (±60.9) | 445 (±85.6) | 2591 (±413.0) | 47 (±2.8) | + |
| MHI 1758 | 1053 (±215.0) | 699 (±109.0) | 961 (±56.6) | 2755 (±166.2) | 52 (±4.2) | * |
+ positive reaction; * not analyzed.
Figure 1(A) Partial NheB sequences comprising amino acid 121–180. The complete Clustal Omega alignment file is given as Figure S1. Although several primers were applied, sequencing of MHI 3225 was only partially possible for unknown reasons. The most prominent difference is the point mutation at position E151D compared to the reference strain MHI 241. This mutation is not present in a formerly-published rNheB fragment, which always tested negative in EIA and Western blot; (B) position of the aspartic acid residue in the structural model of NheB; and (C) the glutamic acid residue is protuding more and slightly rotated in the model.
Figure 2(A) Examples of the Duopath® Assay results for the mutant strains MHI 2970, MHI 1668, and MHI 1541. Undiluted supernatants were added to the lateral flow device. All strains showed a positive reaction for Nhe; (B) dilution series of a typical low-producer (MHI 3178) compared to one of the mutant strains (MHI 2970). A positive reaction is visible up to a dilution of 1:100 for the low-producer but only up to 1:10 for the mutant strain. The arrows point to the NheB band; the pink C on the device shows control band.
Figure 3Western blot results of the membranes probed with mAB 2B11 (upper panel) and 1E11 (lower panel). Except for the low-producer, for which an adjustment of the NheB amounts was impossible, all strains reacted similarly with mAb 1E11. Loaded amounts were adjusted to contain similar NheB levels as calculated based on the indirect EIA results. Under denaturing conditions mAb 2B11 is capable of detecting NheB in all supernatants, with varying intensities. Mean signal for the probed membrane with mAb 1E11 was 219 RLU (±18.5), and 145 RLU (±70.2) for mAb 2B11, thus indicating a lower reactivity, as well as a higher degree of variability for this antibody.